In vitro activity of amphotericin B cochleates against Leishmania chagasi

AUTOR(ES)

Sesana, Aretha Molina, Monti-Rocha, Renata, Vinhas, Solange Alves, Morais, Carlos Gustavo, Dietze, Reynaldo, Lemos, Elenice Moreira

FONTE

Memórias do Instituto Oswaldo Cruz

DATA DE PUBLICAÇÃO

2011-03

RESUMO

Cochleate delivery vehicles are a novel lipid-based system with potential for delivery of amphotericin B (AmB). In this study, the efficacy of cochleates was evaluated by examining the in vitro activity of AmB cochleates (CAMB) against Leishmania chagasi in a macrophage model of infection. We demonstrate that CAMB is nontoxic to macrophages at concentrations as high as 2.5 μg/mL, whereas the conventional formulation, AmB deoxycholate, showed high toxicity at this concentration. The in vitro activity of CAMB against L. chagasi was found to be similar to that of the reference drug AmB deoxycholate, with ED50s of 0.017 μg/mL and 0.021 μg/mL, respectively. Considering that L. chagasi affects organs amenable to cochleate-mediated delivery of AmB, we hypothesize that CAMB will be an effective lipid system for the treatment of visceral leishmaniasis.

Documentos Relacionados

• In vitro activity of atovaquone against Leishmania chagasi promastigotes.
• Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model
• Activity of a Heat-Induced Reformulation of Amphotericin B Deoxycholate (Fungizone) against Leishmania donovani
• Combined Activity of Minocycline and Amphotericin B In Vitro Against Medically Important Yeasts
• Comparative In Vitro Antifungal Activity of Amphotericin B and Amphotericin B Methyl Ester